Please assess the completion status of the following clinical trial:

Trial Title: Topical Ruxolitinib Lichen Planus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Subjects must be able to understand and comply with the requirements of the study and communicate with the investigator.~Subjects must give written, signed, and dated informed consent before any study related activity is performed.~When appropriate, a legal representative will sign the informed consent according to local laws and regulation~Both men and women must be at least 18 years of age at the time of screening~Subjects must have clinical and histological features of LP~LP must involve between 2 and 20% of the BSA~Subjects must have a minimum of 10 lesions of LP~Subjects must have treatment naive cutaneous LP or treatment refractory disease, as defined by failure of at least one established treatment for LP~Failure of prior therapy Topical treatment Systemic immunosuppressant Oral metronidazole Oral sulfasalazine Oral retinoid

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- INCB018424 (Type: EXPERIMENTAL): INCB018424 Cream

Based on this trial design, predict the completion outcome and termination type (if applicable).